KR900003371B1 - 설파모일벤조산 유도체의 제조방법 - Google Patents
설파모일벤조산 유도체의 제조방법 Download PDFInfo
- Publication number
- KR900003371B1 KR900003371B1 KR1019850009043A KR850009043A KR900003371B1 KR 900003371 B1 KR900003371 B1 KR 900003371B1 KR 1019850009043 A KR1019850009043 A KR 1019850009043A KR 850009043 A KR850009043 A KR 850009043A KR 900003371 B1 KR900003371 B1 KR 900003371B1
- Authority
- KR
- South Korea
- Prior art keywords
- formula
- benzoic acid
- derivative
- acid derivatives
- uric acid
- Prior art date
Links
- KDNIOKSLVIGAAN-UHFFFAOYSA-N 2-sulfamoylbenzoic acid Chemical class NS(=O)(=O)C1=CC=CC=C1C(O)=O KDNIOKSLVIGAAN-UHFFFAOYSA-N 0.000 title claims abstract description 8
- 238000004519 manufacturing process Methods 0.000 title description 2
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 9
- 125000003545 alkoxy group Chemical group 0.000 claims abstract description 3
- 125000000217 alkyl group Chemical group 0.000 claims abstract description 3
- -1 methylenedioxy Chemical group 0.000 claims abstract description 3
- 150000004885 piperazines Chemical class 0.000 claims description 6
- 239000002253 acid Substances 0.000 claims description 2
- 229910052801 chlorine Inorganic materials 0.000 claims description 2
- 125000001309 chloro group Chemical group Cl* 0.000 claims description 2
- 125000005843 halogen group Chemical group 0.000 claims description 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 2
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 claims description 2
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 abstract 2
- 229910052736 halogen Inorganic materials 0.000 abstract 1
- 150000002367 halogens Chemical class 0.000 abstract 1
- 230000001077 hypotensive effect Effects 0.000 abstract 1
- 230000000894 saliuretic effect Effects 0.000 abstract 1
- 230000003424 uricosuric effect Effects 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 description 17
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 description 14
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 description 13
- 230000029142 excretion Effects 0.000 description 13
- 229940116269 uric acid Drugs 0.000 description 13
- 230000000694 effects Effects 0.000 description 12
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 8
- 238000002474 experimental method Methods 0.000 description 7
- 241000700159 Rattus Species 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 6
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 4
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- 206010020772 Hypertension Diseases 0.000 description 3
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 238000004140 cleaning Methods 0.000 description 3
- 239000002934 diuretic Substances 0.000 description 3
- 230000001882 diuretic effect Effects 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 239000002244 precipitate Substances 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- FWEOJIHINZZOHE-UHFFFAOYSA-N 4-(2-methoxyphenyl)piperazin-1-amine Chemical compound COC1=CC=CC=C1N1CCN(N)CC1 FWEOJIHINZZOHE-UHFFFAOYSA-N 0.000 description 2
- BWSSMIJUDVUASQ-UHFFFAOYSA-N Benzylhydrochlorothiazide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(S(N2)(=O)=O)=C1NC2CC1=CC=CC=C1 BWSSMIJUDVUASQ-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 201000001431 Hyperuricemia Diseases 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- 241000700157 Rattus norvegicus Species 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- 150000008065 acid anhydrides Chemical class 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 229950007003 benzylhydrochlorothiazide Drugs 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000012267 brine Substances 0.000 description 2
- PFKFTWBEEFSNDU-UHFFFAOYSA-N carbonyldiimidazole Chemical compound C1=CN=CN1C(=O)N1C=CN=C1 PFKFTWBEEFSNDU-UHFFFAOYSA-N 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 238000001647 drug administration Methods 0.000 description 2
- 238000000921 elemental analysis Methods 0.000 description 2
- 238000002844 melting Methods 0.000 description 2
- 230000008018 melting Effects 0.000 description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
- 239000011541 reaction mixture Substances 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- NGNBDVOYPDDBFK-UHFFFAOYSA-N 2-[2,4-di(pentan-2-yl)phenoxy]acetyl chloride Chemical compound CCCC(C)C1=CC=C(OCC(Cl)=O)C(C(C)CCC)=C1 NGNBDVOYPDDBFK-UHFFFAOYSA-N 0.000 description 1
- 125000004204 2-methoxyphenyl group Chemical group [H]C1=C([H])C(*)=C(OC([H])([H])[H])C([H])=C1[H] 0.000 description 1
- FHQAWINGVCDTTG-UHFFFAOYSA-N 4-chloro-3-sulfamoylbenzoic acid Chemical compound NS(=O)(=O)C1=CC(C(O)=O)=CC=C1Cl FHQAWINGVCDTTG-UHFFFAOYSA-N 0.000 description 1
- SCYSJFKWFQZRJW-UHFFFAOYSA-N 4-chloro-3-sulfamoylbenzoyl chloride Chemical compound NS(=O)(=O)C1=CC(C(Cl)=O)=CC=C1Cl SCYSJFKWFQZRJW-UHFFFAOYSA-N 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
- JZUFKLXOESDKRF-UHFFFAOYSA-N Chlorothiazide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC2=C1NCNS2(=O)=O JZUFKLXOESDKRF-UHFFFAOYSA-N 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- 206010019909 Hernia Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 229920001202 Inulin Polymers 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 230000007059 acute toxicity Effects 0.000 description 1
- 231100000403 acute toxicity Toxicity 0.000 description 1
- 239000000010 aprotic solvent Substances 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 238000006482 condensation reaction Methods 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 229940030606 diuretics Drugs 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 229960002003 hydrochlorothiazide Drugs 0.000 description 1
- 230000001631 hypertensive effect Effects 0.000 description 1
- 239000002198 insoluble material Substances 0.000 description 1
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 description 1
- 229940029339 inulin Drugs 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 229910000027 potassium carbonate Inorganic materials 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- DBABZHXKTCFAPX-UHFFFAOYSA-N probenecid Chemical compound CCCN(CCC)S(=O)(=O)C1=CC=C(C(O)=O)C=C1 DBABZHXKTCFAPX-UHFFFAOYSA-N 0.000 description 1
- 229960003081 probenecid Drugs 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 229940066771 systemic antihistamines piperazine derivative Drugs 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/22—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with hetero atoms directly attached to ring nitrogen atoms
- C07D295/28—Nitrogen atoms
- C07D295/32—Nitrogen atoms acylated with carboxylic or carbonic acids, or their nitrogen or sulfur analogues
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
- C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
- C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
- C07D317/48—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
- C07D317/62—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to atoms of the carbocyclic ring
- C07D317/66—Nitrogen atoms not forming part of a nitro radical
Abstract
내용 없음.
Description
제 1 도는 실시예 1의 화합물과 다른 약제의 요산 배설활성을 나타낸다(도면누락).
본 발명은 이뇨활성과 요산 배설활성이 있는 하기 일반식(I)의 신규한 설파모일벤조산 유도체의 제조방법에 관한 것이다.
상기식에서, R1은 염소원자 또는 페녹시 그룹이고, R2는 수소원자, 할로겐원자, 저급알킬그룹, 저급알콕시그룹 또는 메틸렌디옥시 그룹이다.
본 발명의 유도체는 강력한 염분 배설활성, 요산 배설활성 및 혈압 강하활성이 있다. 따라서, 본 발명의 화합물은 간(liver) 질병 또는 심장 질병, 특히 심부전에 수반되는 부종, 고혈압, 과요산혈증 등의 치료용약제로서 중요하다.
본 발명에 따르는 일반식(I)의 화합물은 일반식(II)의 설파모일벤조산 또는 이의 반응성 유도체를 축합제의 존재하에 일반식(III)의 피페라진 유도체와 반응시켜 제조할 수 있다.
상기식에서, R1및 R2는 상기에서 정의한 바와같다.
설파모일벤조산 유도체(II)와 피페라진 유도체(III)와의 반응은 N, N'-디사이클로헥실카보디이미드, N,N'-카보닐디이미다졸등의 축합제의 존재하에 수행한다.
상기의 반응은 축합제를 화합물(II)와 (III)의 혼합물에 가하여 수행한다. 또한, 먼저 화합물(II)를 축합제를 존재하에 이의 산 무수물로 전환시키고, 이어서 산 무수물을 화합물(III)과 반응시키는 축합반응이 편리하다. 이러한 반응에 적절한 용매는 클로로포름, 테트라하이드로푸란, 디메틸포름아미드등의 비양자성 용매이다.
설파모일벤조산의 반응성 유도체(II)를 피페라진 유도체(III)와 반응시키는 경우, 산 클로라이드 또는 산브로마이드를 반응성 유도체로서 사용한다. 이러한 경우에 트리에틸아민, 피리딘, 탄산나트륨, 탄산칼륨등이 축합제로서 사용되고, 벤젠, 톨루엔, 클로로포름, 디클로로메탄, 테트라하이드로푸란등이 용매로서 사용된다.
본 발명을 더욱 상세히 이해할 수 있도록 하기 실시예를 제공한다.
[실시예 1]
4-클로로-N-[4-(2-메톡시페닐)-1-피페라지닐-3-설파모일벤즈아미드
5ml의 테트라하이드로푸란중의 1.8g의, N, N'-디사이클로헥실카보디이미드의 용액에 20ml의 테트라하이드로푸란중의 2.1g의 4-클로로-3-설파모일벤조산의 용액을 실온에서 교반하면서 가한다. 첨가를 완결한 후에, 혼합물을 실온에서 20분간 교반하고, 0.83g의 1-아미노-4-(2-메톡시페닐)피페라진을 가한 다음,반응 혼합물을 5시간 동안 교반한다. 이어서 5ml의 10% 염산을 가하고, 실온에서 10분간 교반한다. 250ml의 2% 수산화나트륨 용액을 가하고, 불용성 물질을 여과해 낸다. 여액을 2%수산화나트륨 용액으로 알칼리화시켜 백색 침전물을 수득한다. 생성된 침전물을 여과하고, 물로 세척한 다음, 에탄올로부터 재결정화하여 융점이 232 내지 235℃인 표제 화합물을 무색 결정으로서 0.84g(수율 : 49%) 수득한다.
C18H2lClN4O4S에 대한 원소분석
계산치(%) : C : 50.88, H : 4.98, N ; 13.19
실측치(%) : C : 51.06, H : 5.02, N;13.19
[실시예 2]
4-클로로-N-[4-(2-메톡시페닐 )-1-피페라지닐-3-설마모일벤즈아미드
1g의 1-아미노-4-(2-메톡시페닐)피페라진 및 1ml의 트리에틸아민의 혼합물에 1.25g의 4-클로로-3-설파모일벤조일 클로라이드를 실온에서 교반하면서 가한다. 반응 혼합물을 실온에서 9시간 동안 교반한다. 생성된 침전물을 여과하고, 물로 세척한 다음, 에탄올로부터 재결정화하여 융점이 231 내지 233℃인 표에 화합물을 무색 침상 결정으로서 1.20g(수율 : 60%) 수득한다.
C18H21ClN4O4S에 대한 원소분석
계산치(%) : C ; 50.88, H : 4.98, N ; 13.19
실측치(%) : C ; 50.58, H : 5.19, N ; 13.15
실시예 2에서 기술한 과정과 동일한 과정으로 제조한 다른 신규 화합물은 표 1에 기재되어 있다.
[표 1]
* : 1/3 H2O, * * : 1/9 H2O, * * * : 2/5 H2O.
본 발명의 화합물의 유용성을 입증하는 실험은 다음과 같다.
[실험 1]
이뇨 및 염분 배설효과
체중이 약 300g인 위스타(wistar)종 래트(수컷)를 사용한다. 각 군은 5마리로 이루어진다. 먹이와 물의 공급을 18시간 동안 중지시킨 다음, 본 발명의 화합물과 참조 약제를 경구투여한다. 결과는 표 2에 기재한다. 실시예 1 및 6의 화합물은 강력한 이뇨제이고 염분 배설특성을 나타낸다.
[표 2] 이뇨 및 염분 배설효과
Na+,K+: 나트륨 및 칼륨의 총 배설량(mEq/kg).
UV : 소변 용량(ml/kg).
Behyd : 벤질하이드로클로로티아지드
HCT : 하이드로클로로티아지드
*,* * : 대조군과 각각 P〈0.05, P〈0.01만큼 다름.
[실험 2]
요산 배설효과
청소(clearance) 시험을 11 내지 14주된 위스타종래트(수컷)로 수행한다. 각 군은 5마리로 이루어진다. 요산 배설활성은 청소비율(요산 청소/이눌린 청소)로 평가한다. 결과는 제 1 도에 나타낸다. 제 1 도에서 종축은 염수 대조군에 대한 요산 배설활성의 %변화를 표시한다. 횡축은 약제 투여후의 시간(분)을 표시한다. 실시예 1의 화합물이 요산 배설 약제로 공지된 프로베네시드(Probenecid)보다 더 강력한 요산 배설효과가있다는 것은 명백하다.
[실험 3]
급성 요산 부하된 래트에서의 과요산혈증 치료효과
10주된 위스타종 래트(수컷)를 본 실험에 사용한다. 약제를 투여하기 30분 전에 200mg/kg 용량의 요산을 래트에게 복강내 투여한다. 실시예 1의 화합물과 프로베네시드를 복강내 투여한다. 30분후에 래트를 사혈로 치사시킨다. 피를 모아 혈청 요산농도를 측정한다. 표 3은 실시예 1의 화합물이 과요산혈증 치료 활성이 있음을 나타낸다.
[표 3] 급성 요산 부하된 래트의 헐청 요산농도
* : 염수와 p〈0.05 다름
[실험 4]
고헐압 치료효과
실시예 1의 화합물을 100mg/kg의 용량으로 4일간 경구투여하면 자연발생적 고혈압성 래트의 심장수축혈압이 저하된다. 데이타는 표 4에 기재한다.
[표 4] 고혈압 치료효과
* : 염수와 P〈0.05 다름
[실험 5]
[급성 독성]
2,500mg/kg 용량의 실시예 1의 화합물을 경구 투여시 ICR종 마우스의 어느 것도 죽지 않았다.
Claims (1)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP256877 | 1984-12-04 | ||
JP59256877A JPS61134382A (ja) | 1984-12-04 | 1984-12-04 | 新規なスルファモイル安息香酸誘導体およびその製造法 |
Publications (2)
Publication Number | Publication Date |
---|---|
KR860004864A KR860004864A (ko) | 1986-07-14 |
KR900003371B1 true KR900003371B1 (ko) | 1990-05-16 |
Family
ID=17298651
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1019850009043A KR900003371B1 (ko) | 1984-12-04 | 1985-12-03 | 설파모일벤조산 유도체의 제조방법 |
Country Status (13)
Country | Link |
---|---|
US (1) | US4650871A (ko) |
EP (1) | EP0186796B1 (ko) |
JP (1) | JPS61134382A (ko) |
KR (1) | KR900003371B1 (ko) |
CN (1) | CN1012642B (ko) |
AU (1) | AU569812B2 (ko) |
CA (1) | CA1241960A (ko) |
DE (1) | DE3573253D1 (ko) |
DK (1) | DK167760B1 (ko) |
ES (1) | ES8702394A1 (ko) |
FI (1) | FI80686C (ko) |
HU (1) | HU194200B (ko) |
NO (1) | NO168245C (ko) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2027898A6 (es) * | 1991-01-24 | 1992-06-16 | Espanola Prod Quimicos | Procedimiento de preparacion de nuevos derivados de la 2-metoxifenilpiperacina. |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2663707A (en) * | 1951-06-22 | 1953-12-22 | American Cyanamid Co | Amino piperazines and methods of preparing the same |
FR1448711A (fr) * | 1960-11-09 | 1966-03-18 | Sandoz Sa | Nouveaux dérivés de l'hydrazine et leur préparation |
US3200121A (en) * | 1964-08-05 | 1965-08-10 | Searle & Co | Disubstituted-alkanoyl hydrazides of 1-aminopiperazines |
FR2104930B1 (ko) * | 1970-09-08 | 1974-08-30 | Ferlux | |
DE2611705A1 (de) * | 1976-03-18 | 1977-09-22 | Josef Dipl Chem Dr Rer N Klosa | N-5-(nitrofurfuryliden-)-1-amino- hydantoin enthaltende kristalloesungsmittel |
CA1082181A (en) * | 1976-06-03 | 1980-07-22 | Eric A. Watts | Benzamide derivatives |
GB8303946D0 (en) * | 1983-02-12 | 1983-03-16 | Recordati Chem Pharm | Antihypertensive n-piperazinylalkanoylanilides |
-
1984
- 1984-12-04 JP JP59256877A patent/JPS61134382A/ja active Granted
-
1985
- 1985-11-27 AU AU50431/85A patent/AU569812B2/en not_active Ceased
- 1985-11-29 FI FI854745A patent/FI80686C/fi not_active IP Right Cessation
- 1985-12-02 CA CA000496626A patent/CA1241960A/en not_active Expired
- 1985-12-03 DK DK559185A patent/DK167760B1/da not_active IP Right Cessation
- 1985-12-03 US US06/804,123 patent/US4650871A/en not_active Expired - Fee Related
- 1985-12-03 DE DE8585115296T patent/DE3573253D1/de not_active Expired
- 1985-12-03 EP EP85115296A patent/EP0186796B1/en not_active Expired
- 1985-12-03 NO NO854872A patent/NO168245C/no unknown
- 1985-12-03 CN CN85108940A patent/CN1012642B/zh not_active Expired
- 1985-12-03 KR KR1019850009043A patent/KR900003371B1/ko not_active IP Right Cessation
- 1985-12-04 HU HU854643A patent/HU194200B/hu not_active IP Right Cessation
- 1985-12-04 ES ES549559A patent/ES8702394A1/es not_active Expired
Also Published As
Publication number | Publication date |
---|---|
JPH0434997B2 (ko) | 1992-06-09 |
ES549559A0 (es) | 1987-01-01 |
NO168245C (no) | 1992-01-29 |
FI80686B (fi) | 1990-03-30 |
DK559185A (da) | 1986-06-05 |
CN1012642B (zh) | 1991-05-22 |
AU5043185A (en) | 1986-06-12 |
DK559185D0 (da) | 1985-12-03 |
KR860004864A (ko) | 1986-07-14 |
US4650871A (en) | 1987-03-17 |
CN85108940A (zh) | 1986-10-22 |
JPS61134382A (ja) | 1986-06-21 |
DK167760B1 (da) | 1993-12-13 |
CA1241960A (en) | 1988-09-13 |
AU569812B2 (en) | 1988-02-18 |
DE3573253D1 (en) | 1989-11-02 |
ES8702394A1 (es) | 1987-01-01 |
EP0186796B1 (en) | 1989-09-27 |
FI854745A (fi) | 1986-06-05 |
EP0186796A1 (en) | 1986-07-09 |
FI80686C (fi) | 1990-07-10 |
HUT40428A (en) | 1986-12-28 |
HU194200B (en) | 1988-01-28 |
FI854745A0 (fi) | 1985-11-29 |
NO168245B (no) | 1991-10-21 |
NO854872L (no) | 1986-06-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2950616B2 (ja) | トリテルペン誘導体 | |
US4569939A (en) | Diuretic 6-vinyl-furo-(3,4-c)-pyridine derivatives | |
FI78297B (fi) | Foerfarande foer framstaellning av farmaceutiskt anvaendbara teofyllinderivat. | |
HU193258B (en) | Process for preparing piperazine derivatives and acid addition salts thereof | |
JPH02304080A (ja) | 6H―ジベンゾ[b,d]ピラン―6―オン誘導体,その製法及び用途 | |
JPS6025423B2 (ja) | 1,4−ジヒドロピリジンの製法 | |
KR930002100B1 (ko) | 2, 3-디히드로벤조푸란-5-설폰아미드 유도체의 제조방법 | |
US4420619A (en) | Imidazole urea and amido compounds | |
KR900003371B1 (ko) | 설파모일벤조산 유도체의 제조방법 | |
NO770161L (no) | Tiazolidinderivater og fremgangsm}te til deres fremstilling. | |
JP2504000B2 (ja) | グルコシルモラノリン誘導体 | |
CN114478522B (zh) | 一种吡啶并咪唑类衍生物及其制备方法与应用 | |
US3914219A (en) | 3-Alkyl-4-sulfamoyl-aniline compounds | |
JPS6323191B2 (ko) | ||
JPH0131502B2 (ko) | ||
FI62664B (fi) | Foerfarande foer framstaellning av nya terapeutiskt anvaendbara 6-piperazinyl-11-metylen-morfantridin-derivat | |
PL93821B1 (ko) | ||
RU2225866C1 (ru) | Калиевая соль 2-[5(6)-нитро-1-(тиетанил-3)-бензимидазолил-2-тио]уксусной кислоты, проявляющая кардиотоническую активность | |
US3876641A (en) | Salt of n-methyl-piperazine and 1,2-diphenyl-3,5-dioxo-4-n-butyl pyrazolidine | |
JP2000044584A (ja) | アミノ酸誘導体・オキソバナジウム(iv)錯体 | |
JPS5935400B2 (ja) | 5−ニトロイミダゾ−ル誘導体の製造法 | |
JPS62255479A (ja) | 新規なスルフアモイル安息香酸誘導体およびその製造法 | |
US3991188A (en) | 3-Alkyl-4-sulfamoyl-aniline therapeutic compositions | |
JPS61152660A (ja) | ビス−ジオキソピペラジン誘導体 | |
KR900003882B1 (ko) | H₂항히스타민 활성을 갖는 화합물의 제조방법 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
G160 | Decision to publish patent application | ||
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant | ||
FPAY | Annual fee payment |
Payment date: 19940310 Year of fee payment: 5 |
|
LAPS | Lapse due to unpaid annual fee |